NCYT.L Stock: Novacyt S.A. Stock Price, Analysis & Insights
Get live ncyt.l stock price $37.52, comprehensive Novacyt S.A. stock analysis, charts, news, and expert forecast. Real-time ncyt.l stock data and investment insights.
Loading chart...
Company Overview
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Company Information
- CEO
- Lyn Dafydd Rees
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 234
Contact Information
- Website
- https://www.novacyt.com
- Address
- 13 Avenue Morane Saulnier
- Country
- FR
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Novacyt S.A. operates in the Medical - Devices industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Lyn Dafydd Rees, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Devices model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Novacyt S.A. competes in the Medical - Devices within the broader Healthcare. With 26.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the London Stock Exchange, Novacyt S.A. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Novacyt S.A. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Novacyt S.A. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Novacyt S.A.
- ⚠Investors should consider how Novacyt S.A. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
26.50M
P/E Ratio
-0.92
Beta
1.11
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 26.50M market capitalization
- Trading Volume: 10.53K shares traded today
- Price Range: 52-week range of $36.00 - $69.00
- Exchange: Listed on London Stock Exchange
Financial Metrics
Market Analysis for Novacyt S.A.
Novacyt S.A. (NCYT.L) operates in the Medical - Devices industry within the Healthcare sector. With a current market capitalization of 26.50M, the company represents a significant player in its market. The stock is currently trading at $37.52 with a negativedaily change of 1.14%.
The company's 234 employee base and presence on the London Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.92, beta of 1.11, and 52-week price range from $36.00 to $69.00when evaluating investment opportunities.
Why Invest in Novacyt S.A.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (London Stock Exchange)
- • Experienced leadership under Lyn Dafydd Rees
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.